Symbols

LEGN

Legend Biotech·NASDAQ

--(--)

LEGN fundamentals

LEGN Q4 2025 Earnings

Legend Biotech (LEGN) released its earnings on Mar 10, 2026: revenue was 306.30M (YoY +64.22%), missed estimates; EPS was -0.08 (YoY -214.29%), missed estimates.

Revenue / YoY

306.30M

+64.22%

EPS / YoY

-0.08

-214.29%

Report date

Mar 10, 2026

LEGN Earnings Call Summary for Q4,2025

CARVYKTI Growth Accelerates: Q4 2025 sales $555M (+66% YoY), with 50.4-month PFS in triple-class exposed patients.
Profitability Milestone: CARVYKTI franchise profitable in 2025; company-wide profitability expected in 2026.
Community Adoption Surge: 1/3 U.S. treatment centers are regional hospitals, 50% doses administered outpatient.
Pipeline Momentum: First in vivo CAR-T data expected in 2026; 1-2 U.S. IND filings planned.
Financial Strength: $949M cash, 61% gross margin, operating loss narrowed 75% YoY.

Earnings

EPS

Revenue

Revenue & Expenses

LEGN has released its 2025 Q4 earnings report, with revenue of 306.38M, reflecting a YoY change of 64.21%, and net profit of -30.82M, showing a YoY change of -217.12%. The Sankey diagram below clearly presents LEGN's revenue sources and cost distribution.

Key Indicators

Legend Biotech (LEGN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Legend Biotech (LEGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Legend Biotech (LEGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Legend Biotech (LEGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown